PharmaCon 2019: 5th China International Chemical Pharmaceutical R&D Forum

As a member of the chemical pharmaceutical industry, you may have questions in today’s market situation

MAH System, "4+7" Volume-Based Procurement, and National Reimbursement Drug List & Adjuvant Drug CatalogHow will it be implemented?

How to Conduct Injections, Poorly Soluble Formulations, and Sustained-Release PreparationsBE Studies and Consistency Evaluation?

Sustained- and Controlled-Release Formulations, Poorly Soluble Formulations, Novel Carrier-Based FormulationsEncountering Technical Challenges in Formulation Design and Process Development?

How New/Generic DrugsDomestic and international regulatory registration?

China Chemical Pharmaceutical Industry Association and Shangtu InformationCo-hosted byPharmaCon 2019: The 5th China International Chemical Drug R&D Forum, helping you find the answer!

●  Exploring the Latest Trends in Generic Drug Regulations, Market, and Technology

●50+ Authoritative Speakers from China and Abroad

●  600+ Most Professional Attendees

●  Three Sub-Forums Conduct In-Depth Analyses of Consistency Evaluation, High-End Formulations, and Domestic and International Regulatory Submissions

●  Understanding the Implementation of the MAH System and Its Future Prospects

●  Exploring Price Setting and Market Breakthroughs After the “4+7” Volume-Based Procurement

●  Discussion on the Impact of the National Reimbursement Drug List & Adjunctive Medication Catalog on Corporate R&D

●Key Technical Points for the Consistency Evaluation of Injectable Drugs

● Mastering Leading Practices and Experience in the Consistent Development of Poorly Soluble Formulations

● Addressing Technical Challenges in the Reference Listed Drugs and Bioequivalence of Sustained-Release Formulations

●  Discussion on Bioequivalence Studies and Consistency Evaluation of High-End Formulations

●Listening to the Latest Advances in Pharmaceutical Research on Orally Administered Poorly Soluble Drug Products

●  Optimizing Dissolution Technology and Process Development for Poorly Soluble Formulations to Enhance Bioavailability

●Study on In Vitro-In Vivo Correlation (IVIVC) and Formulation Design of Oral Sustained- and Controlled-Release Preparations

●Exploration of Formulation Design and Process Development for Pellets, Osmotic Pump Preparations, and Other Dosage Forms

● Analyzing the Development Challenges of Sustained-Release Injectables to Enhance Efficacy and Stability

●  Tracking the Latest Regulatory Developments and Submission and Approval Principles Under China’s New Pharmaceutical Policies

● Listening to Regulatory Submission Strategies and Leading Practices Under European and American Regulations

●  Mastering eCTD International Standards and Writing Requirements

●  Addressing Common Issues in Corporate eCTD Submissions Under ICH Guidelines to Enhance Submission Efficiency

Jan Welink, Chair of the EMA Pharmacokinetics Working Party (PKWP)

Stefan Horkovics-Kovats, BE Expert, Sandoz (Austria)

Hugues Malonne, Director of Marketing Authorization at the Belgian Federal Agency for Medicines and Health Products

Ridha Beliba, Head of Clinical PK at the French National Agency for the Safety of Medicines and Health Products (ANSM), EMA Expert

Liu Chun, Director of the Chemical Drug Division, Department of Drug Registration, China Food and Drug Administration

Brian Berry, Senior Director of Science and Legal Affairs at United Laboratories Ltd.

Xu Mingzhe, Deputy Director of the Division of Chemical Drug Testing, National Institutes for Food and Drug Control

Shen Lingjia, Former Deputy General Manager of Jiangsu Hengrui Medicine Co., Ltd.

Yang Yongjian, Chief Expert and Chief Pharmacist at the Shanghai Institute for Food and Drug Control

Tony Tong, Former Vice President of Teva Pharmaceuticals

Zhao Dong, Deputy Director of the Research Institute, Sichuan Kelun Pharmaceutical Co., Ltd.

●Senior pharmaceutical industry professionals (primarily covering regulatory affairs, medicinal chemistry, formulation, analysis, process development, and manufacturing)

● Regulatory Affairs Expert for Drug Registration and Regulatory Agencies

● Clinical Trial Investigators, Data Management Personnel, Project Management Personnel

●Senior Executives of CROs and Technical Equipment

Suitable Types of Sponsor Companies:

Companies Providing Pharmaceutical CRO Services (Bioequivalence Studies, Analytical Testing, Formulation Development, Drug Discovery, and Synthesis)

A CRO company providing clinical trials, bioequivalence (BE) studies, safety assessments, and eCTD writing services.

A Company Providing Regulatory Services for New Chemical Drugs and Generic Drugs

"Companies Providing CMO Services for Pharmaceuticals"

Equipment and Consumables for Pharmaceutical Analysis and Pre-analytical Processing

Provision of raw materials, intermediates, and packaging materials required for the research, development, and production of chemical drugs.

Information Consulting and Intellectual Property Services Company

moreKeynote Speeches, Lanyard & Badge Advertising, Booth Exhibitors, insert advertisements, dinner sponsorships, tea break sponsorships, roll-up banner exhibitors, and other display opportunities.

Scan the QR code to visit the official website for conference details.

For more conference information, please contact the Organizing Committee!

Tel: +86 180 1793 9885

Email: pharmacon@bmapglobal.com

Website: www.bmapglobal.com/pharmacon2019